Intellia (NTLA) stock fell 3% after successful Phase 3 HAELO trial data. Treatment showed 87% attack reduction. FDA filing begun, 2027 U.S. launch expected.
Browsing: Stocks
SpaceX files for IPO targeting $1.75-$2T valuation. Starlink revenue hits $11.4B with 63% margins, outpacing major telecom competitors.
Qualcomm (QCOM) stock rallied 11% premarket as analyst Ming-Chi Kuo revealed OpenAI’s partnership with QCOM and MediaTek for AI smartphone processors.
POET Technologies (POET) stock doubled on confirmed Marvell supply deal for 800G optical engines, reaching an 11-year high before pulling back on profit-taking.
Intel (INTC) stock surged 24% after crushing Q1 earnings with $0.29 EPS vs $0.01 estimate. AI server demand and Tesla foundry deal drive the rally.
Elon Musk’s $150B lawsuit against OpenAI and Sam Altman begins Monday. The trial could derail the company’s $1 trillion IPO and force a nonprofit reversal.
Meta (META) stock drops 2.41% after China’s NDRC vetoes its $2B+ Manus AI acquisition, signaling Beijing’s stance on protecting domestic AI assets.
Citigroup raises Brent crude forecast to $120/barrel while Goldman Sachs increases Q4 target to $90 amid ongoing Strait of Hormuz closure crisis.
Former TSMC engineer sentenced to 10 years for stealing chip secrets. Tokyo Electron fined $4.8M in Taiwan’s first national security IP case.
Budget airlines including Frontier and Avelo are requesting $2.5B in federal aid from the Trump administration as jet fuel costs surge beyond $4 per gallon.
Alphabet (GOOGL) reports Q1 2026 earnings April 29. Analysts forecast $106.89B revenue, 19% YoY growth, and a 5.59% post-earnings move.
BofA says Nvidia (NVDA) trades at a 50% P/E discount despite massive cash flow. Boosting dividends could unlock a major rerating for the stock.
US stock futures retreat as Iran proposes Strait of Hormuz deal. Oil surges above $100 while investors await Big Tech earnings and Fed meeting this week.
Organon (OGN) stock soared 46% after Sun Pharma announced an $11.75B all-cash acquisition at $14/share, creating a top-25 global pharmaceutical company.
SoFi (SOFI) reports Q1 earnings April 29 after record $3.6B revenue in 2025. Analysts maintain Hold rating with $23.27 target amid valuation concerns.